Avanza Fonder AB Has $5.58 Million Stock Position in Edwards Lifesciences Corporation $EW

Avanza Fonder AB increased its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 14.7% during the third quarter, HoldingsChannel reports. The fund owned 71,734 shares of the medical research company’s stock after acquiring an additional 9,173 shares during the quarter. Avanza Fonder AB’s holdings in Edwards Lifesciences were worth $5,579,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. Quantbot Technologies LP bought a new position in shares of Edwards Lifesciences in the first quarter valued at approximately $26,000. Rosenberg Matthew Hamilton purchased a new stake in Edwards Lifesciences in the 2nd quarter valued at $28,000. NewSquare Capital LLC raised its position in Edwards Lifesciences by 57.8% in the 2nd quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock valued at $29,000 after buying an additional 134 shares during the last quarter. Rakuten Securities Inc. lifted its stake in Edwards Lifesciences by 413.7% during the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 302 shares in the last quarter. Finally, Riverview Trust Co boosted its holdings in Edwards Lifesciences by 44.5% during the 2nd quarter. Riverview Trust Co now owns 516 shares of the medical research company’s stock worth $40,000 after acquiring an additional 159 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on EW. Sanford C. Bernstein reissued a “market perform” rating and set a $90.00 price target on shares of Edwards Lifesciences in a research report on Monday, November 3rd. The Goldman Sachs Group set a $104.00 target price on shares of Edwards Lifesciences and gave the stock a “buy” rating in a research report on Friday, October 31st. Royal Bank Of Canada upped their target price on Edwards Lifesciences from $95.00 to $100.00 and gave the company an “outperform” rating in a report on Friday, December 5th. Evercore ISI lifted their price target on Edwards Lifesciences from $88.00 to $92.00 and gave the stock an “outperform” rating in a report on Friday, October 31st. Finally, Wells Fargo & Company set a $100.00 price objective on Edwards Lifesciences in a research note on Thursday, December 18th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $93.95.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $86.29 on Friday. The firm has a market capitalization of $50.07 billion, a P/E ratio of 37.19, a PEG ratio of 3.88 and a beta of 0.97. Edwards Lifesciences Corporation has a one year low of $65.94 and a one year high of $87.89. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.00 and a quick ratio of 3.29. The business has a fifty day moving average price of $83.60 and a 200-day moving average price of $79.51.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The business had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter last year, the company earned $0.67 EPS. The firm’s revenue was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. As a group, equities research analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,019 shares of the firm’s stock in a transaction on Friday, December 12th. The shares were sold at an average price of $84.03, for a total value of $85,626.57. Following the completion of the transaction, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,848,828.06. This trade represents a 4.43% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 11,386 shares of the business’s stock in a transaction on Friday, December 12th. The shares were sold at an average price of $83.76, for a total transaction of $953,691.36. Following the transaction, the vice president owned 38,970 shares of the company’s stock, valued at $3,264,127.20. This trade represents a 22.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 45,465 shares of company stock worth $3,804,610 in the last three months. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.